I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027. This leadership expansion follows the September 1, 2026, acquisition of Crinetics. Charles Wagner will oversee Crinetics integration, while Jasper van Grunsven joins as EVP for pain and new product planning on September 8, 2026.
- Vertex expanded its executive leadership team following the close of its Crinetics acquisition on Sept. 1, 2026. * Charles Wagner, EVP and chief operating and financial officer, took on oversight of the Crinetics integration, effective immediately. * Jonathan Poole will become EVP, chief financial officer on Jan. 1, 2027; he has led global finance since March 2020. * Poole previously served as CFO of Evelo Biosciences, CFO of Genocea Biosciences, and SVP of finance at Shire. * Jasper van Grunsven joins on Sept. 8, 2026 as EVP, chief pain and new product planning officer; most recently SVP at Amgen. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260831179821) on September 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)